What is ixempra used for?
Uses: Ixempra is used to treat metastatic breast cancer after other chemotherapy medicines have stopped working. It can be given alone or in combination with Xeloda.
Is ixempra a pill?
Ixempra is an injectable cancer medicine. Ixempra is used to treat advanced breast cancer. Ixempra is used alone or with another cancer medicine called capecitabine. Ixempra is usually given after other treatments have failed.
What is the drug ixabepilone used for?
Ixabepilone injection is used alone or in combination with capecitabine to treat breast cancer that cannot be treated with other medications. Ixabepilone is in a class of medications called microtubule inhibitors. It works by killing cancer cells.
How is ixempra administered?
IXEMPRA must be administered at a final infusion concentration of 0.2 mg/mL to 0.6 mg/mL. Are in-line filters required to administer IXEMPRA? The infusion must be administered through an appropriate in-line filter with a microporous membrane of 0.2 to 1.2 microns.
Does ixempra cause hair loss?
Temporary hair loss may occur. Normal hair growth should return after treatment has ended. Many people using this medication have serious side effects. However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk of side effects.
Is ixabepilone a chemotherapy?
Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes.
What are the side effects of bendamustine?
Common side effects
- Increased risk of getting an infection.
- Breathlessness and looking pale.
- Bruising, bleeding gums or nosebleeds.
- Feeling or being sick.
- Skin rash.
- Tiredness and weakness.
- Loss of fertility.
- Sore mouth.
Is lapatinib approved?
On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor ( …
What drug class is lapatinib?
Lapatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.
What drug class is bendamustine?
Bendamustine is in a class of medications called alkylating agents. It works by killing existing cancer cells and limiting the growth of new cancer cells.
What drug class is Lapatinib?
Who manufactures Lapatinib?
Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly U.S.) and Tyverb (mostly Europe and Russia).
Is Lapatinib a chemotherapy drug?
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine.
Does chemo affect your teeth?
Chemotherapy and radiation therapy may cause changes in the lining of the mouth and the salivary glands, which make saliva. This can upset the healthy balance of bacteria. These changes may lead to mouth sores, infections, and tooth decay.
Does chemo make you fart?
Chemotherapy may also alter the normal bacterial flora that is present in the intestines. This can affect digestion and cause aching, cramping or flatulence (gas).
What is another name for bendamustine?
Bendamustine is the generic name for the chemotherapy drug Treanda ®. In some cases, health care professionals may use the trade name Treanda ® when referring to the generic drug name Bendamustine. Drug Type: Bendamustine is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
Is bendamustine FDA approved?
The U.S. Food and Drug Administration has approved Bendeka (bendamustine hydrochloride) injection for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent, B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing …